このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PROCEPT BioRobotics マネジメント

マネジメント基準チェック /34

PROCEPT BioRobotics'の CEO はReza Zadnoで、 Feb2020年に任命され、の在任期間は 4.33年です。の年間総報酬は$ 6.09Mで、 10.1%給与と89.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.23%を直接所有しており、その価値は$ 7.28M 。経営陣と取締役会の平均在任期間はそれぞれ4.3年と3.5年です。

主要情報

Reza Zadno

最高経営責任者

US$6.1m

報酬総額

CEO給与比率	10.1%
CEO在任期間	4.3yrs
CEOの所有権	0.2%
経営陣の平均在職期間	4.3yrs
取締役会の平均在任期間	3.5yrs

経営陣の近況

Recent updates

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

May 21

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

Apr 05

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

Mar 10

CEO報酬分析

PROCEPT BioRobotics の収益と比較して、Reza Zadno の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$103m
Dec 31 2023	US$6m	US$613k	-US$106m
Sep 30 2023	n/a	n/a	-US$107m
Jun 30 2023	n/a	n/a	-US$105m
Mar 31 2023	n/a	n/a	-US$98m
Dec 31 2022	US$4m	US$575k	-US$87m
Sep 30 2022	n/a	n/a	-US$77m
Jun 30 2022	n/a	n/a	-US$69m
Mar 31 2022	n/a	n/a	-US$64m
Dec 31 2021	US$1m	US$490k	-US$60m
Sep 30 2021	n/a	n/a	-US$57m
Jun 30 2021	n/a	n/a	-US$55m
Mar 31 2021	n/a	n/a	-US$53m
Dec 31 2020	US$4m	US$435k	-US$53m

報酬と市場: Rezaの総報酬 ($USD 6.09M ) は、 US市場 ($USD 6.80M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Rezaの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Reza Zadno (69 yo)

4.3yrs

在職期間

US$6,088,813

報酬

Dr. Reza Zadno, Ph D., has been the President, Chief Executive Officer and Director at Procept Biorobotics Corporation since February 2020. Dr. Zadno served as the Chief Executive Officer at Avedro, Inc. f...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Reza Zadno	President	4.3yrs	US$6.09m	0.23% $ 7.0m
Kevin Waters	Executive VP & CFO	5.7yrs	US$2.67m	0.11% $ 3.5m
Alaleh Nouri	EVP, Chief Legal Officer & Corporate Secretary	5.9yrs	US$2.19m	0.032% $ 995.8k
Hisham Shiblaq	Executive VP & Chief Commercial Officer	5.3yrs	US$2.63m	0.015% $ 461.0k
Mohan Sancheti	Senior Vice President of Operations	no data	データなし	データなし
Barry Templin	Executive VP of Technology & Clinical Development	less than a year	データなし	データなし
Matthew Bacso	Vice President of Investor Relations	no data	データなし	データなし
Stacey Porter	Chief People Officer	less than a year	データなし	データなし
Bijesh Chandran	Senior Vice President of Regulatory Affairs & Quality Assurance	2.4yrs	データなし	データなし

4.3yrs

平均在職期間

48yo

平均年齢

経験豊富な経営陣: PRCTの経営陣は経験豊富であると考えられます ( 4.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Reza Zadno	President	4.3yrs	US$6.09m	0.23% $ 7.0m
Frederic Moll	Independent Chairman of the Board	12.8yrs	US$277.64k	1.57% $ 48.3m
Taylor Harris	Independent Director	3.5yrs	US$254.92k	0.26% $ 7.8m
Thomas Krummel	Independent Director	13.5yrs	US$249.92k	0.089% $ 2.7m
Larry Wood	Independent Director	less than a year	データなし	データなし
Elisabeth Sandoval-Little	Independent Director	2.7yrs	US$242.16k	0.016% $ 477.9k
Mary Garrett	Independent Director	2.5yrs	US$244.92k	0.018% $ 550.7k
Antal Desai	Independent Director	9yrs	US$247.42k	0.83% $ 25.4m
Amy Dodrill	Independent Director	3yrs	US$252.42k	0.0092% $ 281.4k

3.5yrs

平均在職期間

62yo

平均年齢

経験豊富なボード: PRCTの取締役会は経験豊富であると考えられます ( 3.5年の平均在任期間)。

PROCEPT BioRobotics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Independent Director notifies of intention to sell stock

PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 04, 2024

President recently sold US$263k worth of stock

Executive VP & CFO exercised options to buy US$2.6m worth of stock.

President recently sold US$428k worth of stock

Independent Director notifies of intention to sell stock

Recent updates

PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) P/S Is Still On The Mark Following 37% Share Price Bounce

PROCEPT BioRobotics Corporation Announces Long-Term, Real-World Data Showing the Benefits of Aquablation Therapy for the Treatment of Symptomatic Prostatic Hyperplasia

Independent Director notifies of intention to sell stock

Price target increased by 13% to US$65.00

Procept Biorobotics Corporation Increases Revenue Guidance for Full Year 2024

First quarter 2024 earnings released: US$0.51 loss per share (vs US$0.63 loss in 1Q 2023)

PROCEPT BioRobotics Corporation, Annual General Meeting, Jun 04, 2024

The Price Is Right For PROCEPT BioRobotics Corporation (NASDAQ:PRCT)

PROCEPT BioRobotics Corporation to Report Q1, 2024 Results on May 01, 2024

President recently sold US$263k worth of stock

Executive VP & CFO exercised options to buy US$2.6m worth of stock.

President recently sold US$428k worth of stock

Independent Director notifies of intention to sell stock

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Price target increased by 11% to US$56.67

PROCEPT BioRobotics Corporation Provides Revenue Guidance for the Full Year 2024

Full year 2023 earnings: EPS misses analyst expectations

Executive VP & CFO notifies of intention to sell stock

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Price target increased by 7.3% to US$51.17

Price target increased by 12% to US$50.33

Executive VP & CFO exercised options and sold US$702k worth of stock

PROCEPT BioRobotics Corporation to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 7.6% to US$47.17

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Independent Chairman of the Board recently sold US$3.1m worth of stock

Executive VP & CFO notifies of intention to sell stock

Price target decreased by 7.9% to US$40.67

Independent Director recently sold US$805k worth of stock

Independent Director notifies of intention to sell stock

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2023

PROCEPT BioRobotics Corporation to Report Q3, 2023 Results on Nov 01, 2023

Procept Biorobotics Corporation Receives U.S. Fda Investigational Device Exemption to Investigate Aquablation Therapy for Prostate Cancer

PROCEPT Biorobotics Corporation Announces First Commercial Aquablation Therapy Procedures in Japan

Price target decreased by 7.6% to US$47.29

PROCEPT BioRobotics Corporation has completed a Follow-on Equity Offering in the amount of $149.999972 million.

Insider exercised options and sold US$280k worth of stock

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2023

PROCEPT BioRobotics Corporation to Report Q2, 2023 Results on Jul 27, 2023

Executive VP & CFO recently sold US$795k worth of stock

Insider exercised options to buy US$366k worth of stock.

First quarter 2023 earnings: EPS misses analyst expectations

President recently sold US$170k worth of stock

Executive VP & CFO recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

No longer forecast to breakeven

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

PROCEPT BioRobotics Corporation to Report Q4, 2022 Results on Feb 28, 2023

Now 22% undervalued

High number of new directors

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

PROCEPT BioRobotics Corporation Projects Earnings Guidance for the Full Year 2022

Now 20% undervalued

PROCEPT BioRobotics Corporation to Report Q3, 2022 Results on Nov 03, 2022

Procept Biorobotics announces $52M debt refinancing

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Procept BioRobotics Has Resources To Ramp Up Commercialization

PROCEPT BioRobotics Corporation Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.43 loss per share (vs US$2.61 loss in 2Q 2021)

PROCEPT BioRobotics Corporation to Report Q2, 2022 Results on Aug 04, 2022

PROCEPT BioRobotics Corporation(NasdaqGM:PRCT) dropped from Russell 2500 Value Index

Independent Director exercised options and sold US$663k worth of stock

BioRobotics Corporation Announces Additional Positive Coverage Policies Regarding Aquablation Therapy for Men with Enlarged Prostates

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

PROCEPT BioRobotics Corporation Revises Revenue Guidance for the Full Year 2022

マネジメント基準チェック /34